Related references
Note: Only part of the references are listed.Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement
Jeannine S. McCune et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
B. S. Andersson et al.
BONE MARROW TRANSPLANTATION (2017)
Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee
Jeanne Palmer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
Imke H. Bartelink et al.
Lancet Haematology (2016)
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
Edward A. Copelan et al.
BLOOD (2013)
Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation
Janelle B. Perkins et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
G. J. Veal et al.
EUROPEAN JOURNAL OF CANCER (2012)
The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: A Global Proficiency Testing Program
David Burger et al.
THERAPEUTIC DRUG MONITORING (2011)
Busulfan in hematopoietic stem cell transplant setting
Jeannine S. McCune et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen
Michelle Geddes et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Optimization of allogeneic transplant conditioning: not the time for dogma
H. J. Deeg et al.
LEUKEMIA (2006)
Cost-effectiveness of therapeutic drug monitoring - A systematic review
DJ Touw et al.
THERAPEUTIC DRUG MONITORING (2005)
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
HJ Deeg et al.
BLOOD (2002)
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation
JS McCune et al.
BONE MARROW TRANSPLANTATION (2002)
Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation
AM Bolinger et al.
BONE MARROW TRANSPLANTATION (2001)
Plasma concentration monitoring of busulfan - Does it improve clinical outcome?
JS McCune et al.
CLINICAL PHARMACOKINETICS (2000)
An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease
AM Bolinger et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
